Therapeutic potential of fecal microbiota transplantation - PubMed (original) (raw)

Review

. 2013 Nov;145(5):946-53.

doi: 10.1053/j.gastro.2013.08.058. Epub 2013 Sep 7.

Affiliations

• PMID: 24018052
• DOI: 10.1053/j.gastro.2013.08.058

Review

Therapeutic potential of fecal microbiota transplantation

Loek P Smits et al. Gastroenterology. 2013 Nov.

Abstract

There has been growing interest in the use of fecal microbiota for the treatment of patients with chronic gastrointestinal infections and inflammatory bowel diseases. Lately, there has also been interest in its therapeutic potential for cardiometabolic, autoimmune, and other extraintestinal conditions that were not previously considered to be associated with the intestinal microbiota. Although it is not clear if changes in the microbiota cause these conditions, we review the most current and best methods for performing fecal microbiota transplantation and summarize clinical observations that have implicated the intestinal microbiota in various diseases. We also discuss case reports of fecal microbiota transplantations for different disorders, including Clostridium difficile infection, irritable bowel syndrome, inflammatory bowel diseases, insulin resistance, multiple sclerosis, and idiopathic thrombocytopenic purpura. There has been increasing focus on the interaction between the intestinal microbiome, obesity, and cardiometabolic diseases, and we explore these relationships and the potential roles of different microbial strains. We might someday be able to mine for intestinal bacterial strains that can be used in the diagnosis or treatment of these diseases.

Keywords: CDI; Clostridium difficile infection; FMT; Fecal Transplantation; Gutmicrobiota; Human Disease; IBD; NAFLD; NASH; SCFA; Therapy; UC; fecal microbiota transplantation; inflammatory bowel disease; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; short-chain fatty acid; ulcerative colitis.

Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

PubMed Disclaimer

Similar articles

• Fecal microbiota transplantation: past, present and future.
  Aroniadis OC, Brandt LJ. Aroniadis OC, et al. Curr Opin Gastroenterol. 2013 Jan;29(1):79-84. doi: 10.1097/MOG.0b013e32835a4b3e. Curr Opin Gastroenterol. 2013. PMID: 23041678 Review.
• An overview of fecal microbiota transplantation: techniques, indications, and outcomes.
  Brandt LJ, Aroniadis OC. Brandt LJ, et al. Gastrointest Endosc. 2013 Aug;78(2):240-9. doi: 10.1016/j.gie.2013.03.1329. Epub 2013 May 2. Gastrointest Endosc. 2013. PMID: 23642791 Review. No abstract available.
• Fecal microbiota transplantation: facts and controversies.
  van Nood E, Speelman P, Nieuwdorp M, Keller J. van Nood E, et al. Curr Opin Gastroenterol. 2014 Jan;30(1):34-9. doi: 10.1097/MOG.0000000000000024. Curr Opin Gastroenterol. 2014. PMID: 24241245 Review.
• Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond.
  Vindigni SM, Broussard EK, Surawicz CM. Vindigni SM, et al. Expert Rev Gastroenterol Hepatol. 2013 Sep;7(7):615-28. doi: 10.1586/17474124.2013.832501. Expert Rev Gastroenterol Hepatol. 2013. PMID: 24070153 Review.
• Fecal microbiota transplantation for gastrointestinal diseases.
  Matsuoka K, Mizuno S, Hayashi A, Hisamatsu T, Naganuma M, Kanai T. Matsuoka K, et al. Keio J Med. 2014;63(4):69-74. doi: 10.2302/kjm.2014-0006-RE. Epub 2014 Dec 15. Keio J Med. 2014. PMID: 25500625 Review.

Cited by

• The gut microbiota improves reproductive dysfunction in obese mice by suppressing the NLRP3/ASC/caspase-1 axis.
  Huang H, Zhou T, He F, Wen B, Yang Y, Zhong W, Wang Q, Li J. Huang H, et al. Future Microbiol. 2024;19(16):1389-1405. doi: 10.1080/17460913.2024.2386867. Epub 2024 Sep 3. Future Microbiol. 2024. PMID: 39225491
• The Role of Fecal Microbiota Transplantation (FMT) in the Management of Metabolic Diseases in Humans: A Narrative Review.
  Zikou E, Koliaki C, Makrilakis K. Zikou E, et al. Biomedicines. 2024 Aug 16;12(8):1871. doi: 10.3390/biomedicines12081871. Biomedicines. 2024. PMID: 39200335 Free PMC article. Review.
• Dual Regulation Mechanism of Obesity: DNA Methylation and Intestinal Flora.
  Ren Y, Huang P, Zhang L, Tang YF, Luo SL, She Z, Peng H, Chen YQ, Luo JW, Duan WX, Liu LJ, Liu LQ. Ren Y, et al. Biomedicines. 2024 Jul 23;12(8):1633. doi: 10.3390/biomedicines12081633. Biomedicines. 2024. PMID: 39200098 Free PMC article. Review.
• Roseburia intestinalis-derived extracellular vesicles ameliorate colitis by modulating intestinal barrier, microbiome, and inflammatory responses.
  Han HS, Hwang S, Choi SY, Hitayezu E, Humphrey MA, Enkhbayar A, Song DG, Kim M, Park JS, Park YT, Park JS, Cha KH, Choi KY. Han HS, et al. J Extracell Vesicles. 2024 Aug;13(8):e12487. doi: 10.1002/jev2.12487. J Extracell Vesicles. 2024. PMID: 39166405 Free PMC article.
• Exploring the Multifaceted Therapeutic Potential of Probiotics: A Review of Current Insights and Applications.
  Chakravarty K, Gaur S, Kumar R, Jha NK, Gupta PK. Chakravarty K, et al. Probiotics Antimicrob Proteins. 2024 Jul 28. doi: 10.1007/s12602-024-10328-x. Online ahead of print. Probiotics Antimicrob Proteins. 2024. PMID: 39069588 Review.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Medical

  • MedlinePlus Health Information